Standard BioTools (NASDAQ:LAB) Stock: Insider Thomas Carey Buys 75,000 Shares

Posted by Geri Gentry on Nov 7th, 2026

Standard BioTools Inc. (NASDAQ:LAB – Get Free Report) Director Thomas Carey acquired 75,000 shares of the company’s stock in a transaction on Thursday, November 5th. The shares were acquired at an average price of $0.63 per share, for a total transaction of $47,250.00. Following the completion of the acquisition, the director directly owned 419,456 shares in the company, valued at $264,257.28. The trade was a 21.77% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Standard BioTools Stock Performance

Shares of NASDAQ:LAB opened at $0.64 on Friday. Standard BioTools Inc. has a twelve month low of $0.59 and a twelve month high of $1.72. The business has a fifty day moving average of $0.68 and a 200-day moving average of $0.90.

Standard BioTools (NASDAQ:LAB – Get Free Report) last issued its earnings results on Tuesday, November 3rd. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.05. Standard BioTools had a negative return on equity of 7.57% and a net margin of 100.36%. The business had revenue of $19.39 million during the quarter, compared to analyst estimates of $18.80 million.

Institutional Investors Weigh In On Standard BioTools

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new stake in shares of Standard BioTools in the 2nd quarter worth approximately $6,791,000. Sone Capital Management LLC acquired a new stake in Standard BioTools during the 2nd quarter worth approximately $1,755,000. Staley Capital Advisers Inc. acquired a new position in Standard BioTools in the 1st quarter valued at $581,000. Man Group plc acquired a new position in Standard BioTools during the second quarter valued at approximately $611,000. Finally, GSA Capital Partners LLP bought a new position in shares of Standard BioTools during the 2nd quarter valued at about $977,000. Institutional investors own 53.74% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Standard BioTools in a research note on Wednesday. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Reduce”.

Check Out Our Latest Analysis on Standard BioTools

Standard BioTools Company Profile

(Get Free Report)

Standard BioTools Inc (NASDAQ: LAB) develops and supplies technologies, instruments and consumables used by researchers and biopharmaceutical companies to analyze biological systems. Its portfolio supports applications in proteomics, genomics, single-cell analysis, mass cytometry and spatial biology.

The company’s offerings include the SomaScan protein profiling platform, which measures large numbers of proteins from biological samples, as well as CyTOF mass cytometry systems for high-dimensional single-cell analysis.